AI-Powered Summary
Market Context
Top Queries
More News
Explore Prysm Tools
Related Stories
Kilitch Drugs (India) Ltd. Q3 FY26 Certificate Under SEBI Regulation 74(5)
Kilitch Drugs (India) Limited
January 15, 2026, 06:17 AM
Kilitch Drugs (India) Limited received a certificate from its RTA, MUFG Intime India Private Limited, for the quarter ended December 31, 2025. This confirms compliance with SEBI (Depositories and Participants) Regulations, 2018, regarding the dematerialisation of securities.
Top Queries to Ask About Kilitch Drugs (India) Limited
InstantThinking to buy or sell Kilitch Drugs (India) Limited? Ask AI before you act.
Trusted by 5,000+ users
More Details on This News
Kilitch Drugs (India) Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This certificate pertains to the quarter ended December 31, 2025.
The company received this confirmation from MUFG Intime India Private Limited, its Registrar and Share Transfer Agent. The certificate confirms that the securities received from depository participants for dematerialisation during the specified quarter were processed, and the security certificates were duly mutilated, cancelled, and replaced with depository entries in the register of members within the stipulated timelines.
This is a routine compliance filing to ensure proper record-keeping and adherence to SEBI regulations regarding the dematerialisation of securities.
More News on Kilitch Drugs (India) Limited
Analyze Kilitch Drugs (India) Limited